Core Points - The company is appointing Zhengdan Zhiyuan (Shenzhen) CPA Firm to audit the revised 2023 financial statements due to a change in profit and loss status from profit to loss as per the regulatory requirements [4][10] - The board of directors has approved the appointment of the CPA firm with a unanimous vote and is now seeking shareholder approval [10][12] Group 1: Appointment of CPA Firm - The CPA firm Zhengdan Zhiyuan (Shenzhen) was selected based on its qualifications and ability to meet the company's auditing needs for the revised financial statements [9][10] - The firm has a history of providing auditing services, with 16 listed company clients in 2024, including 13 in manufacturing and 2 in information technology [6][9] - The firm has no recent criminal or administrative penalties, indicating a strong compliance record [7][8] Group 2: Board of Directors' Actions - The board has nominated Mr. Wang Qingtang as a candidate for a non-independent director position, pending shareholder approval [12] - The nomination is part of the company's efforts to enhance its corporate governance structure [12] - Mr. Wang has relevant experience and qualifications, having served in various roles within the company since 2006 [13]

上海盟科药业股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688373 证券简称：盟科药业 上海盟科药业股份有限公司 会议资料 二 O 二五年七月 上海盟科药业股份有限公 司 2025 年第一次临时股东大会会议资料 上海盟科药业股份有限公司 上海盟科药业股份有限公司 2025 年第一次临时股东大会会议资料 上海盟科药业股份有限公司 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》以及《上海盟科 药业股份有限公司章程》（以下简称"《公司章程》"）、《上海盟科药业股份有限公 司股东大会议事规则》等相关规定，上海盟科药业股份有限公司（以下简称"公司"） 特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将 对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东或其代理人的合法权益， 务请出席大会的股东或其代理人或其他出席者至少提前 ...

Core Viewpoint - Shanghai Hehe Information Technology Co., Ltd. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global capital operation capabilities and brand recognition, while also revising its corporate governance structure and internal rules to align with this strategic move [6][9][24]. Group 1: Shareholder Meeting Proposals - Proposal to cancel the supervisory board and amend the company's articles of association, transferring the supervisory board's powers to the audit committee of the board of directors [6][24]. - Proposal for the issuance of H-shares and listing on the Hong Kong Stock Exchange, which has been approved by the board and supervisory board [9][14]. - Proposal to authorize the board of directors to handle all matters related to the H-share issuance and listing [17][23]. Group 2: Governance and Internal Rules - Proposals to revise various internal governance documents, including the rules for shareholder meetings, board meetings, and independent director work systems, to ensure compliance with new regulations following the H-share issuance [7][8][24]. - The company plans to adjust its internal governance documents based on changes in laws and regulations, as well as the requirements of regulatory bodies [20][24]. Group 3: Fund Utilization - The funds raised from the H-share issuance will be used for enhancing AI technology research, product innovation, global expansion, and general corporate purposes [16][24]. - The board seeks authorization to adjust the use of raised funds based on operational needs and regulatory feedback [21][24].